IPS Biopharma

27.01.2019

IPS Biopharma AG is a privately held, Swiss immuno-oncology focused biotech company developing a potentially first-in-class immunotherapy for solid tumor cancers. The company’s lead drug candidate, IP-001, is designed to initiate a patient-specific, well-tolerated, systemically active immune response against a patient’s individual cancer. IP-001, also known as N-dihydrogalactochitosan, is injected intratumorally after a standard-of-care tumor ablation to initiate the immunotherapy. Unique molecular properties and the novel mechanism of action enables IP-001 to trap and retain tumor-targeting information and promote a robust immune response that attacks both the ablated tumor and distant metastases.

Encouraging early clinical data showed shrinkage of both local tumors and distant metastases after ablation + IP-001 treatment. In some patients, this led to elimination of the cancer with long-lasting response. The company has partnered with the Swiss Group for Clinical Cancer Research (SAKK) for clinical trial development and implementation of its Swiss phase I/II multicenter study that addresses significant clinical unmet need in various indications.

IPS Biopharma AG is an Immunophotonics subsidiary and is supported by the Swiss Foundation for Technological Innovation (STI), be-advanced, the Berne Economic Development Agency (BEDA), is located in the Switzerland Innovation Park and is an active part of the startup community in Switzerland.